EN | TR
E-ISSN: 1307-5608
Comparasion Between Mitotic Activity, Ki-67 Index and Platelet Volume Index as a Prognostic Marker in Gliablastomas
PDF
Cite
Share
Request
Research Article
VOLUME: 72 ISSUE: 2
P: 222-226
August 2019

Comparasion Between Mitotic Activity, Ki-67 Index and Platelet Volume Index as a Prognostic Marker in Gliablastomas

J Ankara Univ Fac Med 2019;72(2):222-226
DOI: 10.4274/atfm.galenos.2019.93584
Tolga Turan Dündar
1. Bezmialem Vakıf Üniversitesi, Beyin ve Sinir Cerrahisi Anabilim Dalı, İstanbul, Türkiye
No information available.
No information available
Received Date: 11.03.2019
Accepted Date: 29.05.2019
Publish Date: 02.10.2019
PDF
Cite
Share
Request

ABSTRACT

Objectives:

An elevated platelet count is considered an independent prediction of survey in glioblastoma and various other intracranial entities. Activity of the tumor microcirculation resulting in platelet activation and release of several cytokines and factors from activated platelets has been suggested to play an active role in neuro-inflammation. Ki-67 index and mitotic activity are markers which could be showed proliferation in the glial tumor. High Ki-67 expression and mitosis rate of high grade glial tumors have been more aggressive clinical progression, poor prognosis, more vascular invasion than low. Recently, Mean Platelet Volume (MPV) to platelet count (PLT) ratio has become a trend indicator to anticipate the outcome of a patient suffering from intracranial pathologies. The study aims to determine first time whether the comparison of the Volume Index (PVI) as an immune response marker with the Ki-67 and mitotic activity could be used as a prognostic factor in gliablastoma (WHO Grade IV).

Materials and Methods:

In the retrospective study, we studied 65 patients diagnosed with glioblastoma who had inclusion and exclusion criteria. The correlation between PVI, Ki-67 and mitotic activity was examined all cases after pathologically diagnosed, by the routine processes of the pathological preparates. PVI was calculated from pre-operative first complete blood count (CBC) and was defined as MPV value (fL)x100/PLT (per 1000). The Kolmogorov-Smirnov test and Spearman’s correlation coefficient was used in the analysis of the interrelationship.

Results:

The correlation between the PVI, Ki-67 and mitotic index was found to be leak statistically correlation.

Conclusion:

It was determined that PVI is decreased, Ki-67 immunoreactivity and mitotic index are increased. The PVI may be used as a prognostic, predictive factor for glioblastoma. Nevertheless, further studies concerning the prognosis of glioblastoma are needed to confirm this hypothesis.

Keywords: Glioblastoma, GBM, Platelets, Mean Platelet Volume, Platelet Volume Index, PVI

References

1
Gusyatiner O, Hegi ME. Glioma epigenetics: From subclassification to novel treatment options. Semin Cancer Biol. 2018;51:50-58.
2
Mineo M, Ricklefs F, Rooj AK. The Long Non-coding RNA HIF1A-AS2 facilitates the maintenance of mesenchymal glioblastoma stem-like cells in hypoxic niches. Cell Rep. 2016;15:2500-2509.
3
Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classification of Tumours of the Central Nervous System: a summary: Acta Neuropathol 2016;131:803-820.
4
Kaynar MY, Dündar TT. Düşük Dereceli Gliomalar ve Tedavileri, Ozyurt ME editör. Beyin Tümörleri Kök Hücresi ve Tümerogenezisi. Cilt 1, Birinci Baskı, İstanbul: 2015;239-251.
5
Stoyanov GS, Dzhenkov DL, Kitanova M, et al. Correlation Between Ki-67 Index, World Health Organization Grade and Patient Survival in Glial Tumors With Astrocytic Differentiation. Cureus. 2017;26;9:e1396.
6
Wong E, Nahar N, Hau E, et al . Cut‐point for Ki‐67 proliferation index as a prognostic marker for glioblastoma. Asia Pac J Clin Oncol. 2019;15:5-9.
7
Hirashima Y, Hamada H, Kurimoto M, et al. Decrease in platelet count as an independent risk factor for symptomatic vasospasm following aneurysmal subarachnoid hemorrhage. J Neurosurg. 2005;102:882-887.
8
Zhou Y, Jiang Y, Peng Y, et al. The Quantitative and Functional Changes of Postoperative Peripheral Blood Immune Cell Subsets Relate to Prognosis of Patients with Subarachnoid Hemorrhage: A Preliminary Study. World Neurosurgery. 2017;206-215.
9
Ray B, Tinsley L, Ford L, et al. Trends of Platelet Volume Index Predicts Delayed Cerebral Ischemia after Subarachnoid Hemorrhage. World Neurosurg. 2018;624-631.
10
Alvarez de Eulate-Beramendi S, Alvarez-Vega MA, Balbin M, et al. Prognostic factors and survival study in high-grade glioma in the elderly. Br J Neurosurg. 2016;30:330-336.
11
Sarıca FB, Yademir F, Cekinmez M, et al. “Yeni Tanı Almış Glioblastoma Hastalarında Temozolomid ile Yapılan Konkomitan Terapi ve Nüks Glioblastoma Olgularında Uygulanan Bevacizumab ve İrinotecan Antianjiyojenik Kombinasyon Terapisi Etkinliği: 10 Yıllık Tedavi Sonuçları”. Türk Nöroşirürji Derg. 2015;1:19-30.
12
Chen WJ, He DS, Tang RX, et al. ChenKi-67 is a valuable prognostic factor in gliomas: evidence from a systematic review and meta-analysis Asian Pac J Cancer Prev. 2015;411-420.
13
Moskowitz SI, JinPrayson T. RA Role of MIB1 in predicting survival in patients with glioblastomas .J Neurooncol. 2006;76:193-200.
14
Kanyılmaz G, Önder H, Aktan M, et al. Prognostic Importance of Ki-67 Labeling Index in Grade II Glial Tumors. Turk J Oncol. 2018;33:48-53.
15
Lin Y, Zhou J, Xu J, et al. Effects of combined radiosurgery and temozolomide therapy on epidermal growth factor receptor and variant III in glioblastoma multiforme. Oncol Lett. 2018;15:5751-5759.
16
Charles N, Holland EC . The perivascular niche microenvironment in brain tumor progression. Cell Cycle. 2010; 9:3012-3021.
17
Charles NA, Holland EC, Gilbertson R, et al. The brain tumor microenvironment. Glia 2012;60:502-514.
18
Marx S, Splittstöhser M, Kinnen F, et al. Platelet activation parameters and platelet-leucocyte-conjugate formation in glioblastoma multiforme patients. Oncotarget. 2018;25;9:25860-25876.
19
Brockmann MA, Bender B, Plaxina E, et al. Differential effects of tumor-platelet interaction in vitro and in vivo in glioblastoma. J Neurooncol. 2011;105:45-56.
20
Nolte I, Przibylla H, Bostel T, et al. Tumor-platelet interactions: glioblastoma growth is accompanied by increasing platelet counts. Clin Neurol Neurosurg. 2008;110:339-342.
21
Mills SJ, du Plessis D, Pal P, et al. Mitotic Activity in Glioblastoma Correlates with Estimated Extravascular Extracellular Space Derived from Dynamic Contrast-Enhanced MR Imaging. AJNR Am J Neuroradiol. 2015;37:811-817.
22
Nielsen LAG, Bangsø JA, Lindahl KH, et al. Evaluation of the proliferation marker Ki-67 in gliomas: Interobserver variability and digital quantification. Diagn Pathol. 2018;13:38-46.
2024 ©️ Galenos Publishing House